Abstract
Importance Genomic analyses solely focused on detecting mutations do not benefit most pediatric cancer patients. Alternate genomic approaches are needed to identify additional treatment biomarkers and therapeutic targets.
Objective To evaluate the performance of our Comparative Analysis of RNA Expression (CARE) pipeline in nominating druggable targets in pediatric patients with difficult-to-treat or rare cancers.
Design, Setting, and Participants Our cohort study, the Comparative Analysis of RNA Expression to Improve Pediatric and Young Adult Cancer Treatment (CARE IMPACT), was conducted collaboratively by the UC Santa Cruz Treehouse Childhood Cancer Initiative and Stanford University School of Medicine. From June 4, 2018, to September 24, 2020, UCSC Treehouse obtained and processed RNA sequencing (RNA-Seq) data for 35 tumor samples from 33 children and young adults with a relapsed, refractory or rare cancer. Each tumor RNA-Seq dataset underwent CARE analysis to reveal activated cancer driver pathways and nominate treatment options. We compare the CARE pipeline to other gene expression outlier detection approaches and discuss challenges and opportunities for the clinical implementation of RNA-Seq-based gene expression outlier detection for pediatric cancer patients.
Exposures Patients underwent tumor RNA-Seq analysis and standard-of-care tumor DNA profiling. UCSC Treehouse compared each patient’s tumor RNA-Seq profile with over 11,000 uniformly analyzed tumor profiles from public data repositories. These comparisons reveal candidate cancer genes and pathways that represent potential therapeutic targets.
Main Outcome(s) and Measure(s) Proportion of patients for whom CARE provided useful clinical and biological information for patient care. Impact of comparator cohort choice on outlier findings.
Results Of our 33 patients, 31 (94%) had CARE IMPACT findings of potential clinical significance. These findings were implemented in 5 patients, 3 of which had defined clinical benefit. We demonstrated that composition of comparator cohorts determines which outliers are detected and that large and diverse cohorts containing data from tumors similar to the patients produce the most clinically relevant outlier results.
Conclusions and Relevance Comparative RNA-Seq analysis may identify additional cancer driver pathways and druggable targets in patients with rare or difficult-to-treat pediatric cancers relative to standard-of-care DNA profiling. This study highlights the clinical utility of CARE for pediatric tumors and underscores the need for further evaluation of this approach to improve patient outcomes.
Questions Is tumor RNA expression information useful for the clinical care of children with difficult-to-treat or rare cancers? How does choice of comparator cohort impact RNA expression results?
Findings In this cohort of 33 pediatric patients, Comparative Analysis of RNA Expression provided useful clinical information for all patients; three of five patients who received treatment derived clinical benefit. We demonstrate the impact of comparator cohort composition on RNA outlier analysis.
Meaning Tumor RNA expression information reveals useful information for the clinical care of pediatric cancer patients. Choice of comparator cohort size and composition impacts gene expression outlier detection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study/authors were funded by the following: California Initiative to Advance Precision Medicine (CIAPM), AACR NextGen Award for Transformative Cancer Research, The St. Baldrick's Foundation, The Live for Others Foundation, Stanford Medicine Children's Health and Stanford University School of Medicine, and Howard Hughes Medical Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional review boards of the University of California Santa Cruz and Stanford University School of Medicine gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† Co-senior authors
The author's list has been updated to list Olena Vaske as the last author.
Data Availability
All data produced are available online at https://treehousegenomics.ucsc.edu/public-data/
